Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/03/2005WO2005048999A3 Use of cyclooxygenase-2 inhibitors for the treatment of depressive disorders
11/03/2005WO2005046657A3 Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
11/03/2005WO2005046608A3 Novel compound, corresponding compositions, preparation and/or treatment methods
11/03/2005WO2005044201A3 Ph sensitive prodrugs of 2,6-diisopropylphenol
11/03/2005WO2005039645A3 Sp1 and sp3 targeted cancer therapies and therapeutics
11/03/2005WO2005027972A3 Combination of a vegf receptor inhibitor with a chemotherapeutic agent
11/03/2005WO2005025511A3 Potassium channel mediated delivery of agents through the blood-brain barrier
11/03/2005WO2005021722A3 METHODS AND COMPOSITIONS FOR INHIBITION OF NUCLEAR FACTOR κB
11/03/2005WO2005020954A3 Proton pump inhibitor formulations, and methods of preparing and using such formulations
11/03/2005WO2005018605A3 Novel formulation of ropinirole
11/03/2005WO2005018569A3 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
11/03/2005WO2005018546A3 Compositions for diabetes treatment and prophylaxis
11/03/2005WO2005016322A3 Pharmaceutical compositions of lavendustin
11/03/2005WO2005016285A3 Compositions and methods for inhibiting slit protein and glypican interactions
11/03/2005WO2005014008A3 Treatment of disorders associated with natural killer t cells
11/03/2005WO2005011611A3 Bicyclic compounds and compositions as pdf inhibitors
11/03/2005WO2005007817A3 Hexameric porphobilinogen synthase as a target for the development of antibiotics and herbicides
11/03/2005WO2005006860A3 Azole derivatives and methods for making the same
11/03/2005WO2005002555A3 Sirt1 modulators for manipulating cell/organism lifespan/stress response
11/03/2005WO2005002518A3 Methods for treating and preventing cardiac arrhythmia
11/03/2005WO2005000240A3 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
11/03/2005WO2004108070A3 Releasable polymeric conjugates based on aliphatic biodegradable linkers
11/03/2005WO2004103301A3 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
11/03/2005WO2004099165A3 Heterocyclic compounds and hydro isomers thereof
11/03/2005WO2004096131A3 Inhibitors of akt activity
11/03/2005WO2004093916A8 A medicament for the two-step perioperative therapy of solid tumours
11/03/2005WO2004089355A8 Compositions for treating microbial and parasitic infections in cattle and other animals
11/03/2005WO2004087073A3 Treatment of demyelinating conditions
11/03/2005WO2004084827A3 Reduction of zinc-induced neurotoxic injury by blockade of nitric oxide synthesis
11/03/2005WO2004082675A8 Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
11/03/2005WO2004080285A3 Amyloid plaque as a target for therapeutics that function by blocking or disrupting chitin synthesis or activity
11/03/2005WO2004072243A3 Macrocyclic hepatitis c serine protease inhibitors
11/03/2005WO2004004660A3 Compositions and methods for the treatment of parkinson’s disease and tardive dyskinesias
11/03/2005WO2003034980A8 A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same
11/03/2005WO2002004440A9 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
11/03/2005US20050245855 A layer of butyl 2-cyanoacrylate applied to a short wound to extend beyond the edges and allowed to set and polymerize; a similar second layer; decreased tensile strength to match that of skin to avoid dehiscence; surgical incisions; joint injuries; antiscarring agents; speedy reepithelialization
11/03/2005US20050245840 Implantable urinary tract monitor
11/03/2005US20050245765 Partially hydrolyzing methyl formates with water; forming a formic acid/water stream; reacting the methyl formate stream with a base in the presence of water; distilling off methanol; and combining the formic acid and water stream with the formate and water stream
11/03/2005US20050245750 Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative
11/03/2005US20050245743 depression and/or anxiety, obesity, urinary disorder; 5-(2-Methoxyphenyl)-N-[3-(4-Piperidinyl)Phenyl]Pentanamide
11/03/2005US20050245741 Novel tricyclic spiropiperidines or spiropyrrolidines
11/03/2005US20050245738 Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
11/03/2005US20050245736 Low molecular weight oversulfated polysaccharide
11/03/2005US20050245618 Polyvinyl alcohol, borate, polysorbate, and benzalkonium chloride preservative, buffer, water; nonprescription
11/03/2005US20050245617 Methods and compositions for the treatment of CNS-related conditions
11/03/2005US20050245616 Ketoamine tumor suppressor reactivators: 3-Acetoxy-2-(acetoxymethyl)-1-oxo-1-phenylpropan-2-ammonium chloride
11/03/2005US20050245614 Oral administering; controlling blood concentration; urogenital disorders; blood disorders
11/03/2005US20050245613 Use of gaba-b receptor positive modulators in gastro-intestinal disorders
11/03/2005US20050245612 Pharmaceutical compositions for metabolic insufficiencies
11/03/2005US20050245611 Administering intravenous valproate such that acute migraine headache is lessened or reduced in subject, wherein about 250 mg to 750 mg of valproate is administered to a subject over 30 minutes to 1 hour
11/03/2005US20050245610 Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
11/03/2005US20050245609 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
11/03/2005US20050245606 High-efficiency fullerene-based radical scavengers
11/03/2005US20050245605 Anhydrous silver dihydrogen citrate compositions
11/03/2005US20050245604 Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester
11/03/2005US20050245602 Selective estrogen receptor modulators
11/03/2005US20050245601 Treatment of diseases involving ErbB2 kinase overexpression
11/03/2005US20050245600 Novel antimalarial agent
11/03/2005US20050245599 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
11/03/2005US20050245598 Antiproliferative activity and is most unlikely a substrate for P-glycoprotein and/or Multidrug Resistant Protein
11/03/2005US20050245597 Darifenacin solvate with toluene; mixing the free base with toluene to form the solvate, converting to the hydrate, addition salt formation with hydrogen bromide; high purity, extended shelf life; irritable bowel syndrome, incontinence and other gastrointestinal disorders
11/03/2005US20050245596 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
11/03/2005US20050245595 Positive modulators of nicotinic receptor agonists
11/03/2005US20050245594 Drug delivery; analgesics; side effect reduction
11/03/2005US20050245592 2-Iminopyrrolidine derivatives
11/03/2005US20050245591 Improved preparation of alpha -polymorphic eletriptan hydrobromide, by salt formation in a solution of 2-butanone and water, distillation, dehydration, desolventizing; purity, white color crystals
11/03/2005US20050245589 Pyrazole phenyl derivatives
11/03/2005US20050245588 Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
11/03/2005US20050245587 Treatment of dyskinesia
11/03/2005US20050245586 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12
11/03/2005US20050245585 Process for preparing optically pure zolmitriptan
11/03/2005US20050245584 Peroxisome proliferator activated receptor agonists
11/03/2005US20050245583 Pesticides for crops; agriculture, horticulture
11/03/2005US20050245580 Novel substituted dihydro 3-halo-1H-pyrazole-T-carboxylates, their preparation and use
11/03/2005US20050245579 desferrithiocin analogs used as siderophores, for treatment of malaria in humans
11/03/2005US20050245578 Polymorphs of pantoprazole sodium salt and process for the preparation thereof
11/03/2005US20050245577 Drug for kidney failure containing oxaluric acid derivative
11/03/2005US20050245576 Substituted pyrazoles
11/03/2005US20050245575 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
11/03/2005US20050245574 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
11/03/2005US20050245573 N-substituted benzene sulfonamides
11/03/2005US20050245571 Amine derivative
11/03/2005US20050245570 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
11/03/2005US20050245567 Novel quinuclidine derivatives and their use
11/03/2005US20050245564 Methods and compositions related to IRM compounds and toll-like receptor pathways
11/03/2005US20050245563 Chk-1 inhibitors
11/03/2005US20050245562 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
11/03/2005US20050245561 Anti-tumour polycyclic carboxamides
11/03/2005US20050245559 Treatment and prevention of prostate cancer
11/03/2005US20050245558 Naltrexone long acting formulations and methods of use
11/03/2005US20050245557 Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
11/03/2005US20050245556 Pharmaceutical preparation containing oxycodone and naloxone
11/03/2005US20050245555 Tri-substituted ureas as cytokine inhibitors
11/03/2005US20050245554 Substituted pyrimidines
11/03/2005US20050245553 Amino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl chloromethanesulfonate; cardiovascular disorders, thromboembolic disorders, inflammation, and disorders of the central nervous system
11/03/2005US20050245552 N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis
11/03/2005US20050245551 Amide derivatives
11/03/2005US20050245549 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
11/03/2005US20050245548 Alkynylated fused ring pyrimidine compounds
11/03/2005US20050245547 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma
1 ... 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 ... 7860